日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Evaluation of entinostat alone and in combination with standard-of-care cytotoxic agents against rhabdomyosarcoma xenograft models

评估恩替诺特单独使用和与标准治疗细胞毒性药物联合使用对横纹肌肉瘤异种移植模型的疗效

Raushan T Kurmasheva, Abhik Bandyopadhyay, Edward Favours, Vanessa Del Pozo, Samson Ghilu, Doris A Phelps, Stephen W Erickson, Cody J Peer, William D Figg, Malcolm A Smith, Peter J Houghton

Evaluation of patritumab with or without erlotinib in combination with standard cytotoxic agents against pediatric sarcoma xenograft models

评估 patritumab 与或不与厄洛替尼联合使用以及与标准细胞毒药物联合治疗儿童肉瘤异种移植模型的效果

Abhik Bandyopadhyay, Edward Favours, Doris A Phelps, Vanessa Del Pozo, Samson Ghilu, Dias Kurmashev, Joel Michalek, Aron Trevino, Denis Guttridge, Cheryl London, Kenji Hirotani, Ling Zhang, Raushan T Kurmasheva, Peter J Houghton

Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program

儿科临床前测试计划对新型 EZH2 抑制剂他泽司他 (EPZ-6438) 进行初步测试(第 1 阶段)

Raushan T Kurmasheva, Melissa Sammons, Edward Favours, Jianwrong Wu, Dias Kurmashev, Katherine Cosmopoulos, Heike Keilhack, Christine R Klaus, Peter J Houghton, Malcolm A Smith